Doug Cole

Doug Cole is the General Partner of Flagship Ventures and he joined Flagship in 2001 where he focuses on Life Science investments. He came to Flagship with significant industry experience and a strong academic background. Doug holds an AB magna cum laude with High Distinction in English from Dartmouth College， where he was a Senior Fellow and a member of Phi Beta Kappa， and an MD from the University of Pennsylvania School of Medicine， where he was a member of Alpha Omega Alpha. He obtained post-graduate training in medicine at the Johns Hopkins Hospital in Baltimore， MD and in neurology at the Massachusetts General Hospital in Boston， MA. In 1992， Doug was appointed Instructor in Neurology at Harvard Medical School and an Assistant in Neurology at the Massachusetts General Hospital. He established a research program investigating the mechanistic basis of neuronal signaling events and plasticity in neuro-psychiatric disorders with the support of the NIH and several non-profit research foundations.

In 1996， Doug joined Cytotherapeutics， in Providence， RI. As Medical Director， he oversaw various research and clinical activities related to the company’s cell-based therapeutic technologies. In 1997， he was appointed Program Executive at Vertex Pharmaceuticals， Inc.， in Cambridge， MA， where he led a multidisciplinary program that conducted preclinical development through Phase II studies in tissue protection and repair， oversaw an international research collaboration， and was responsible for identifying strategic market and technology opportunities in multiple arenas.

At Flagship， Doug has led investments in CombinatoRx， Tetraphase Pharmaceuticals， Alvine Pharmaceuticals， Concert Pharmaceuticals， Quanterix Corporation， Receptos， Agios Pharmaceuticals， Seventh Sense Biosystems， and Avedro. He is a co-founder of Flagship portfolio company Ensemble Therapeutics， Permeon Biologics， and ModeRNA Therapeutics. He currently serves on the Board of Directors of Tetraphase Pharmaceuticals， Concert Pharmaceutical